Pappas Capital LLC
02/26/2013 | Press release | Archived content
Man with a plan: Emil Kakkis aims to lure big-market drugs toward...
News | 02. 26. 2013
Ultragenyx Pharmaceutical
February 26, 2013
Emil Kakkis is making another run at rare diseases.
The president and CEO of Ultragenyx Pharmaceutical Inc. and former chief medical officer at BioMarin Pharmaceutical Inc. is laying out a new strategy Tuesday to get more drugs into children with rare diseases. Under the banner of the EveryLife Foundation for Rare Diseases, which Kakkis founded and has largely bankrolled, he is proposing that companies with already-approved, big-market drugs be rewarded with a two-month extension of that drug's patent life if it wins a new Food and Drug Administration-approved label in an orphan disease.
Pappas Capital LLC published this content on February 26, 2013, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]